Literature DB >> 16647038

Carbohydrate microarrays reveal sulphation as a modulator of siglec binding.

María Asunción Campanero-Rhodes1, Robert A Childs, Makato Kiso, Shiro Komba, Christine Le Narvor, Joanna Warren, Diana Otto, Paul R Crocker, Ten Feizi.   

Abstract

Siglecs are receptors on cells of the immune, haemopoietic, and nervous systems that recognize sialyl-glycans with differing preferences for sialic acid linkage and oligosaccharide backbone sequence. We investigate here siglec binding using microarrays of Lewis(x) (Le(x))- and 3'-sialyl-Le(x)-related probes with different sulphation patterns. These include sulphation at position 3 of the terminal galactose of Le(x), position 6 of the galactose of Le(x) and sialyl-Le(x), position 6 of N-acetylglucosamine of Le(x) and sialyl-Le(x), or both positions of sialyl-Le(x). Recombinant soluble forms of five siglecs have been investigated: human Siglec-7, -8, -9, and murine Siglec-F and CD22 (Siglec-2). Each siglec has a different binding pattern. Unlike two C-type lectins of leukocytes, L-selectin and Langerin, which also bind to sulphated analogues of sialyl-Le(x), the siglecs do not give detectable binding signals with sulphated analogues that are lacking sialic acid. The sulphate groups modulate, however, positively or negatively the siglec binding intensities to the sialyl-Le(x) sequence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647038     DOI: 10.1016/j.bbrc.2006.03.223

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

1.  Structural basis for sulfation-dependent self-glycan recognition by the human immune-inhibitory receptor Siglec-8.

Authors:  Johannes M Pröpster; Fan Yang; Said Rabbani; Beat Ernst; Frédéric H-T Allain; Mario Schubert
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

2.  Involvement of sulfates from cruzipain, a major antigen of Trypanosoma cruzi, in the interaction with immunomodulatory molecule Siglec-E.

Authors:  Maximiliano R Ferrero; Anja M Heins; Luciana L Soprano; Diana M Acosta; Mónica I Esteva; Thomas Jacobs; Vilma G Duschak
Journal:  Med Microbiol Immunol       Date:  2015-06-06       Impact factor: 3.402

3.  Chemoenzymatic synthesis of α2-3-sialylated carbohydrate epitopes.

Authors:  Huang Shengshu; Yu Hai; Chen Xi
Journal:  Sci China Chem       Date:  2011-01       Impact factor: 9.445

Review 4.  Advances in the biology and chemistry of sialic acids.

Authors:  Xi Chen; Ajit Varki
Journal:  ACS Chem Biol       Date:  2010-02-19       Impact factor: 5.100

5.  Distinct substrate specificities of human GlcNAc-6-sulfotransferases revealed by mass spectrometry-based sulfoglycomic analysis.

Authors:  Shin-Yi Yu; Cheng-Te Hsiao; Mineko Izawa; Akiko Yusa; Hiroji Ishida; Shigeo Nakamura; Hirokazu Yagi; Reiji Kannagi; Kay-Hooi Khoo
Journal:  J Biol Chem       Date:  2018-08-09       Impact factor: 5.157

Review 6.  Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors.

Authors:  B S Bochner
Journal:  Clin Exp Allergy       Date:  2009-03       Impact factor: 5.018

Review 7.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 8.  The challenge and promise of glycomics.

Authors:  Richard D Cummings; J Michael Pierce
Journal:  Chem Biol       Date:  2014-01-16

9.  KSGal6ST generates galactose-6-O-sulfate in high endothelial venules but does not contribute to L-selectin-dependent lymphocyte homing.

Authors:  Michael L Patnode; Shin-Yi Yu; Chu-Wen Cheng; Ming-Yi Ho; Lotten Tegesjö; Keiichiro Sakuma; Kenji Uchimura; Kay-Hooi Khoo; Reiji Kannagi; Steven D Rosen
Journal:  Glycobiology       Date:  2012-12-18       Impact factor: 4.313

10.  Potential tumor markers for human gastric cancer: an elevation of glycan:sulfotransferases and a concomitant loss of alpha1,2-fucosyltransferase activities.

Authors:  E V Chandrasekaran; Jun Xue; Conrad Piskorz; Robert D Locke; Károly Tóth; Harry K Slocum; Khushi L Matta
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-11       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.